Molecular Mechanisms linking Aging, Abeta Proteotoxicity and Neurodegeneration

衰老、Abeta 蛋白毒性和神经退行性变之间的分子机制

基本信息

  • 批准号:
    8429423
  • 负责人:
  • 金额:
    $ 184.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-02-01 至 2014-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Aging increases the risk of neurodegeneration. Strong evidence implicates aggregation-mediated proteotoxicity as the cause of neurodegeneration in numerous clinically important diseases, including Alzheimer's disease, although the etiology is unclear. Emerging genetic data suggest that the aging process is linked by signaling pathways to the fidelity of protein homeostasis, including the ability to recover or dispose of misfolded or aggregated proteins. Overall this program project strives to meet two goals: 1) to understand the organismal, cell biological and molecular bases for the pathways that protect organisms from protein aggregation, and 2) to determine how these pathways become compromised as an organism ages. The Kelly Laboratory will focus on the biochemical characterization of the pathway(s) and the underlying molecular determinants of the disaggregase activity that appears to protect against age onset proteotoxicity in C. elegans and murine models of Alzheimer's and in human cells and they will test the hypothesis that amyloidogenesis is a constitutive process. The Balch Laboratory will generate senescence cell models to probe the role of age-dependent changes in exocytic and endocytic APR and Abeta processing that appear to contribute to proteotoxicity and will employ their expertise to perturb the exocytic and endocytic pathways to understand the genesis of Abeta proteotoxicity. The Dillin Laboratory will utilize genetic, proteomic and bioinformatics approaches and animal models of Alzheimer's disease to understand how and which aging-associated signaling pathways and downstream determinants affect proteotoxicity and they will carry out Abeta aggregate structure toxicity assessments in the worm Alzheimer's model. The bioinformatics, proteomics and neurosciences and neuropathology cores are each intimately associated with two or more of these projects that are themselves highly interdependent. The results obtained from this project will not only provide insight into the relationship between aging and neurodegeneration, but should provide the information necessary to develop therapeutic strategies for age-associated neurodegenerative diseases.
描述(由申请人提供):衰老会增加神经退行性变的风险。强有力的证据表明,聚集介导的蛋白毒性是许多临床重要疾病的神经退化的原因,包括阿尔茨海默病,尽管病因尚不清楚。新出现的遗传数据表明,衰老过程通过信号通路与蛋白质稳态的保真度联系在一起,包括恢复或处理错误折叠或聚集的蛋白质的能力。总体而言,该计划项目努力实现两个目标:1)了解保护生物体免受蛋白质聚集的途径的有机体、细胞生物学和分子基础;2)确定这些途径如何随着生物体的老化而受到影响。凯利实验室将专注于该途径的生化特征(S)和解聚酶活性的潜在分子决定因素,该活性似乎可以在线虫和阿尔茨海默病小鼠模型以及人类细胞中防止老年性蛋白毒性,他们将检验淀粉样变是一个结构性过程的假设。Balch实验室将建立衰老细胞模型,以探索与年龄相关的变化在胞外和胞内APR和Abeta加工中的作用,这些变化似乎有助于蛋白毒性,并将利用他们的专业知识扰乱胞外和内胞途径,以了解Abeta蛋白毒性的起源。迪林实验室将利用遗传、蛋白质组和生物信息学方法以及阿尔茨海默氏病的动物模型,了解与衰老相关的信号通路和下游决定因素如何以及哪些影响蛋白毒性,他们将在蠕虫阿尔茨海默氏症模型中进行Abeta聚集体结构毒性评估。生物信息学、蛋白质组学、神经科学和神经病理学的核心都与两个或多个项目密切相关,而这些项目本身又高度相互依存。该项目所取得的成果不仅将深入了解衰老和神经退行性疾病之间的关系,而且还将为制定与年龄相关的神经退行性疾病的治疗策略提供必要的信息。

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Temporal requirements of heat shock factor-1 for longevity assurance.
  • DOI:
    10.1111/j.1474-9726.2012.00811.x
  • 发表时间:
    2012-06
  • 期刊:
  • 影响因子:
    7.8
  • 作者:
    Volovik Y;Maman M;Dubnikov T;Bejerano-Sagie M;Joyce D;Kapernick EA;Cohen E;Dillin A
  • 通讯作者:
    Dillin A
Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition.
  • DOI:
    10.1021/acs.jproteome.1c00550
  • 发表时间:
    2021-12-03
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Wang XD;Kim C;Zhang Y;Rindhe S;Cobb MH;Yu Y
  • 通讯作者:
    Yu Y
Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection.
  • DOI:
    10.1111/j.1474-9726.2009.00541.x
  • 发表时间:
    2010-04
  • 期刊:
  • 影响因子:
    7.8
  • 作者:
    Cohen E;Du D;Joyce D;Kapernick EA;Volovik Y;Kelly JW;Dillin A
  • 通讯作者:
    Dillin A
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.
IGF-1信号传导降低会延迟小鼠年龄相关的蛋白质毒性。
  • DOI:
    10.1016/j.cell.2009.11.014
  • 发表时间:
    2009-12-11
  • 期刊:
  • 影响因子:
    64.5
  • 作者:
    Cohen E;Paulsson JF;Blinder P;Burstyn-Cohen T;Du D;Estepa G;Adame A;Pham HM;Holzenberger M;Kelly JW;Masliah E;Dillin A
  • 通讯作者:
    Dillin A
Immunoprecipitation of amyloid fibrils by the use of an antibody that recognizes a generic epitope common to amyloid fibrils.
  • DOI:
    10.1371/journal.pone.0105433
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Greiner ER;Kelly JW;Palhano FL
  • 通讯作者:
    Palhano FL
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFERY W KELLY其他文献

JEFFERY W KELLY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFERY W KELLY', 18)}}的其他基金

Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
从药理学角度探讨轻链淀粉样变性的蛋白病成分
  • 批准号:
    10440457
  • 财政年份:
    2021
  • 资助金额:
    $ 184.89万
  • 项目类别:
Pharmacologic Lysosomal Flux Activators to Ameliorate Alzheimer's Disease and Related Dementias
药理学溶酶体通量激活剂可改善阿尔茨海默病和相关痴呆症
  • 批准号:
    10281046
  • 财政年份:
    2021
  • 资助金额:
    $ 184.89万
  • 项目类别:
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
从药理学角度探讨轻链淀粉样变性的蛋白病成分
  • 批准号:
    10186362
  • 财政年份:
    2021
  • 资助金额:
    $ 184.89万
  • 项目类别:
Probing the Proteinopathy Component of Light Chain Amyloidosis Pharmacologically
从药理学角度探讨轻链淀粉样变性的蛋白病成分
  • 批准号:
    10625486
  • 财政年份:
    2021
  • 资助金额:
    $ 184.89万
  • 项目类别:
Proteostasis Regulator Pharmacology Core D
蛋白质稳态调节剂药理学核心 D
  • 批准号:
    10183113
  • 财政年份:
    2018
  • 资助金额:
    $ 184.89万
  • 项目类别:
Proteostasis Regulator Pharmacology Core D
蛋白质稳态调节剂药理学核心 D
  • 批准号:
    10432030
  • 财政年份:
    2018
  • 资助金额:
    $ 184.89万
  • 项目类别:
Interplay of Intrinsic and Extrinsic Effects of N-glycans on Glycoproteostasis
N-聚糖对糖蛋白稳态的内在和外在影响的相互作用
  • 批准号:
    9520024
  • 财政年份:
    2015
  • 资助金额:
    $ 184.89万
  • 项目类别:
Interplay of Intrinsic and Extrinsic Effects of N-glycans on Glycoproteostasis
N-聚糖对糖蛋白稳态的内在和外在影响的相互作用
  • 批准号:
    8946941
  • 财政年份:
    2015
  • 资助金额:
    $ 184.89万
  • 项目类别:
Interplay of Intrinsic and Extrinsic Effects of N-glycans on Glycoproteostasis
N-聚糖对糖蛋白稳态的内在和外在影响的相互作用
  • 批准号:
    9116133
  • 财政年份:
    2015
  • 资助金额:
    $ 184.89万
  • 项目类别:
Discovering Small Molecule Activators of Stress-responsive Signaling
发现应激反应信号传导的小分子激活剂
  • 批准号:
    9904304
  • 财政年份:
    2013
  • 资助金额:
    $ 184.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了